Patented Cxbladder urine tests are supported by strong clinical evidence and are positioned for significant market growth, pending anticipated Medicare re-coverage. A NZ$24 million capital raise aims to support ongoing operations, innovation, and expansion, with cost-saving measures reducing cash burn and APAC operations trending toward profitability.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.